I think its more than that. Baxter has been expanding their manufacturing (at least in other areas) and for Biosimilars I imagine MNTA needs a lot more than what they can afford on their own.
The way it is worded I would guess its a 50/50 profit split but I am not sure about development (and later commercialization) costs since the release indicates Baxter making more payments.
Market Data 
Markets 
AI
